Reported 1 day ago
Zoetis Inc. (NYSE:ZTS) has announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency has provided a positive opinion recommending marketing authorization for Portela (reflovetmab), a new monoclonal antibody therapy designed to relieve osteoarthritis pain in cats. If approved, Portela will be the first long-acting anti-nerve growth factor therapy for felines, offering up to three months of pain relief from a single injection, based on a favorable assessment of its safety and efficacy.
Source: YAHOO